Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial

Leticia R. Cruz 1,‡, Idania Baladrón 2‡, Aliusha Rittoles 1, Pablo A. Díaz 2, Carmen Valenzuela 3, Raúl Santana 1, Maria M. Vázquez 2, Ariadna García 1, Deyli Chacón 1, Delvin Thompson 1, Gustavo Perera 1, Ariel González 4, Rafael Reyes 5, Loida Torres 4, Jesus Pérez 1, Yania Valido 1, Raúlsmay Rodríguez 1, Dania M. Vázquez-Bloomquist 2, Mauro Rosales 2,6, Ailyn C. Ramón 2, George V. Pérez 2, Gerardo Guillén 2, Verena Muzio 2, Yasser Perera 2,7, and Silvio E. Perea 2,* for the ATENEA-Co-300 group

Affiliations: 1 Central Hospital “Luis Diaz Soto”, Havana 19130, Cuba, 2 Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba, 3 Center for Molecular Immunology, Havana 11600, Cuba, 4 International Center of Health “La Pradera”, Havana 11600, Cuba, 5 National Institute of Oncology and Radiobiology, Havana 10400, Cuba, 6 Faculty of Biology, University of Havana, Havana 10400, Cuba, 7 China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Yongzhou Zhong Gu Biotechnology Co., Ltd, Hunan 425000, China.

Table of Content

| Data                                                                 | Page Number |
|----------------------------------------------------------------------|-------------|
| Table S1 (Chest-CT evolution considering lesion’s extent)            | S-2         |
Table S1: Chest-CT evolution considering lesion’s extent

| Lesion’s extent (Score 1-5) | Group | I    | II   | Sign. (U-Mann Whitney) |
|-----------------------------|-------|------|------|------------------------|
| Day 0                       | Median ± RI | 4.5 ± 10.0 | 2.0 ± 5.0 | 0.146 |
| (Min; Max)                  |       | (0; 18) | (0; 6) |                        |
| Day 7                       | Median ± RI | 3.5 ± 10.0 | 2.0 ± 3.0 | 0.189 |
| (Min; Max)                  |       | (0; 15) | (0; 6) |                        |
|                            | Sign. (Wilcoxon) | 0.066 | 1.000 |                        |
| Reduction of lesion’s extent| YES   | 4 (66.7%) | 1 (14.3%) | 0.103 |
|                            | NO    | 2 (33.0%) | 6 (85.7%) | (Fisher) |
|                            | Dif. (IC 95%) | 53.2 (3.6; 86.8) | Bayesian analysis | |
|                            | P (Dif>0) | 0.982 | | |

* Per protocol population defined as patients who completed the regimen originally allocated and patients having chest-CT at the beginning and at the end of treatment